Kadcyla (T-DM1) Offers Metastatic Breast Cancer Patients Hope
Recently approved by the FDA, Kadcyla, previously known as T-DM1 during its development, is a drug designed to help women who have stage 3 or stage 4 metastatic breast cancer (cancer that has spread to other areas) that is HER2-positive and resistant to previous breast cancer treatment programs. About twenty percent of breast cancer patients are HER2-positive, which means that their tumors have high levels of a protein called HER2.
Unlike traditional chemotherapy treatments which often affect both tumor and normal cells, Kadcyla (T-DM1) is a targeted therapy that delivers medication to tumor cells directly, without affecting healthy cells. With it’s recent approval by the FDA, Kadcyla is expected to be available to patients in the United States very soon.
Metastatic breast cancer is diagnosed when the breast cancer spreads to other areas in the body. These cancerous tumors are referred to as metastatic tumors. While targeted therapies such as Herceptin help in the treatment of some HER2-positive cancer cases, there are some patients for whom Herceptin, as well as many other cancer treatments do not work. Kadcyla (T-DM1) now offers these patients more hope.
Kadcyla (T-DM1) was chosen as a major advance in breast cancer treatment for 2012 by the American Society of Clinical Oncology (ASCO).